http://www.ncbi.nlm.nih.gov/pubmed/24398701
New Study Shows Positive Results with Bone Marrow Concentrate (BMC) Injection for Knee Osteoarthritis
Bone Marrow Concentrate (BMC) has evolved in recent years as a one of the most promising orthobiologic therapies for Osteoarthritis (OA). The anti inflammatory and regenerative properties of BMC have been shown in early studies to relieve pain and stiffness, as well as improve joint function, in patients suffering from degenerative arthritis. New studies and clinical trials are constantly emerging, adding more evidence supporting BMC use in OA.
The most recent study, published online from the European Journal of Surgery and Traumatology evaluated 41 patients (75 knees) with a mean age of 60.7 years old, diagnosed with degenerative arthritis, who underwent intra articular injection of BMC with adipose tissue. Each patient was assigned a radiologic arthritis score (I-IV) via the Kellgren-Lawrence grading scale, and Pre/Post operative Visual Analogue Score (VAS) and functional scores were used for evaluation at 3, 6, and 12 months.
The study revealed a decrease in the mean VAS from 7.0 preoperatively to 4.1, 3.5, and 3.3 at the 3, 6, and 12 months follow up appointments. Functional improvements were also illustrated via the International Knee Documentation Committee score, SF-36 score, Knee and Osteoarthitis Outcome score, and the Lysholm Knee Questionnaire. However, when the results were classified based on specific radiologic arthritis grade, Grade IV (severe arthritis) had a significantly less decreases in VAS in comparison to grades I-III, with a preoperative value of 8.2, and 5.5, 5.3, 5.7 in the respective follow ups.
The results contribute to the growing research trends supporting the treatment of OA with intra articular injections of BMC. Given the decreased improvements in Grade IV arthritis patients, this study suggests BMC to be more effective in early to moderate phases of degenerative arthritis. Although, further studies are needed to more thoroughly evaluate the efficacy of BMC therapy, this study adds further support to the regenerative potential of Bone Marrow for degenerative joint diseases such as arthritis.
View Abstract: http://link.springer.com/article/10.1007/s00590-013-1393-9
The most recent study, published online from the European Journal of Surgery and Traumatology evaluated 41 patients (75 knees) with a mean age of 60.7 years old, diagnosed with degenerative arthritis, who underwent intra articular injection of BMC with adipose tissue. Each patient was assigned a radiologic arthritis score (I-IV) via the Kellgren-Lawrence grading scale, and Pre/Post operative Visual Analogue Score (VAS) and functional scores were used for evaluation at 3, 6, and 12 months.
The study revealed a decrease in the mean VAS from 7.0 preoperatively to 4.1, 3.5, and 3.3 at the 3, 6, and 12 months follow up appointments. Functional improvements were also illustrated via the International Knee Documentation Committee score, SF-36 score, Knee and Osteoarthitis Outcome score, and the Lysholm Knee Questionnaire. However, when the results were classified based on specific radiologic arthritis grade, Grade IV (severe arthritis) had a significantly less decreases in VAS in comparison to grades I-III, with a preoperative value of 8.2, and 5.5, 5.3, 5.7 in the respective follow ups.
The results contribute to the growing research trends supporting the treatment of OA with intra articular injections of BMC. Given the decreased improvements in Grade IV arthritis patients, this study suggests BMC to be more effective in early to moderate phases of degenerative arthritis. Although, further studies are needed to more thoroughly evaluate the efficacy of BMC therapy, this study adds further support to the regenerative potential of Bone Marrow for degenerative joint diseases such as arthritis.
View Abstract: http://link.springer.com/article/10.1007/s00590-013-1393-9
Eur J Orthop Surg Traumatol. 2014 Jan 8. [Epub ahead of print]
Clinical outcome of autologous bone marrow aspirates concentrate (BMAC) injection in degenerative arthritis of the knee.
Abstract
PURPOSE:
As a treatment method of degenerative arthritis of knee, this study evaluated the clinical efficacy of the intra-articular injection of autologous bone marrow aspirates concentrate (BMAC) with adipose tissue.
MATERIALS AND METHODS:
Between April 2011 and May 2012, 41 patients (75 knees) who were diagnosed as a degenerative knee arthritis and underwent the BMAC injection with adipose tissue were included in this study. Mean age was 60.7 years old (ranged 53-80). Kellgren-Lawrence grade was used for assessing radiologic degree of osteoarthritis; there were each 12, 24, 33, and 6 cases of grade I, II, III, and IV. At preoperative and postoperative 3, 6, and 12 months, pain score using visual analogue scale (VAS) and functional scales were used for evaluation.
RESULTS:
After the procedure, mean VAS score was decreased from 7.0 preoperatively to 4.1, 3.5, and 3.3 postoperatively 3, 6, and 12 months. And functional scores were also improved; International Knee Documentation Committee score (from 37.7 preoperatively to 59.3, 66.3, 69.3 postoperatively), SF-36 health score (from 31.5 to 43.5, 45.6, 47.7), knee and osteoarthritis outcome score (from 43.1 to 64.9, 68.5, 70.6), Lysholm Knee Questionnaire (from 37.3 to 65.4, 68.6, 71.0) were all increased after the procedure. When classified according to K-L grade, the improvement of VAS score in grade IV group was 8.2 preoperatively to 5.5, 5.3, and 5.7 postoperatively, which was significantly poorer than those of grade I-III groups. In the knee functional scales, similar pattern was checked.
CONCLUSIONS:
BMAC injection significantly improved both knee pain and functions in the patients with degenerative arthritis of knee. Also, the injection would be more effective in early to moderate phases.
- PMID:
- 24398701
- [PubMed - as supplied by publisher]
No hay comentarios:
Publicar un comentario